Wealth Effects LLC Takes $803,000 Position in Kenvue Inc. $KVUE

Wealth Effects LLC acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) during the third quarter, Holdings Channel reports. The fund acquired 49,468 shares of the company’s stock, valued at approximately $803,000.

Other institutional investors have also added to or reduced their stakes in the company. Salomon & Ludwin LLC acquired a new position in shares of Kenvue during the third quarter worth approximately $25,000. Trust Co. of Vermont raised its holdings in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares during the last quarter. New England Capital Financial Advisors LLC lifted its stake in shares of Kenvue by 81.4% in the third quarter. New England Capital Financial Advisors LLC now owns 2,563 shares of the company’s stock valued at $42,000 after buying an additional 1,150 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new position in shares of Kenvue during the third quarter valued at about $49,000. Finally, First Pacific Financial bought a new stake in shares of Kenvue during the second quarter worth about $54,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of Kenvue stock opened at $17.13 on Thursday. The business’s fifty day simple moving average is $16.95 and its 200 day simple moving average is $18.32. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The firm has a market capitalization of $32.81 billion, a P/E ratio of 22.83 and a beta of 0.60.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s revenue was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s payout ratio is currently 110.67%.

Insiders Place Their Bets

In related news, Director Jeffrey C. Smith bought 3,200,000 shares of the company’s stock in a transaction on Friday, December 12th. The shares were purchased at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the purchase, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.68% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Bank of America dropped their price target on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a research report on Friday, October 24th. Canaccord Genuity Group reissued a “hold” rating and issued a $15.00 price target (down from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. UBS Group dropped their price objective on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Finally, Citigroup reduced their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $20.23.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.